Literature DB >> 19576036

[Impact of chronic obstructive pulmonary disease on quality of life and economic burden in Chinese urban areas].

Quan-Ying He1, Xin Zhou, Can-Mao Xie, Zong-An Liang, Ping Chen, Chang-Gui Wu.   

Abstract

OBJECTIVE: To assess the impact of chronic obstructive pulmonary disease (COPD) on the quality of life and economic burden in Chinese urban areas.
METHODS: COPD patients (n = 723) were interviewed face-to-face in outpatient departments in 6 large cities in China. The questionnaire included social and demographic information, current health status, quality of life (SGRQ), and medical expenditure on outpatient visit, hospitalization, medicine purchasing in medicine stores in the last 12 months, and other expenditures related with COPD were also collected. All the data were analyzed using descriptive method.
RESULTS: Of the 723 COPD patients interviewed, 73% were male and the average age was 67 years old. The average symptom score of SGRQ was 49 +/- 24, activity score 57 +/- 23, impact score 46 +/- 23 and total score 50 +/- 21, which were all higher than scores of the healthy populations. The average direct medical cost (including outpatient cost, inpatient cost, and medicine purchasing cost) was 11 744 RMB yuan annually. The direct non-medical cost (including transportation fee, nutrition fee, and nursing fee) was 1570 RMB yuan. 36% of the patients in work had an average of 17 working days lost in the last 12 months because of COPD, while 17% of their relatives had an average of 14 working days lost for caring the patients.
CONCLUSIONS: COPD has a serious impact on the quality of life of Chinese urban patients and places a heavy economic burden on their family and the society. Management of COPD should be improved for patients at stable conditions, so as to reduce the incidence and exacerbation of COPD.

Entities:  

Mesh:

Year:  2009        PMID: 19576036

Source DB:  PubMed          Journal:  Zhonghua Jie He He Hu Xi Za Zhi        ISSN: 1001-0939


  14 in total

1.  Chronic obstructive pulmonary disease in China: the potential role of indacaterol.

Authors:  Jinming Gao; Niyati Prasad
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

2.  The REACH Trial: A Randomized Controlled Trial Assessing the Safety and Effectiveness of the Spiration® Valve System in the Treatment of Severe Emphysema.

Authors:  Shiyue Li; Guangfa Wang; Changhui Wang; Xinglin Gao; Faguang Jin; Huaping Yang; Baohui Han; Rui Zhou; Chengshui Chen; Liangan Chen; Chunxue Bai; Huahao Shen; Felix J F Herth; Nanshan Zhong
Journal:  Respiration       Date:  2018-12-14       Impact factor: 3.580

Review 3.  Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPD.

Authors:  Jinming Gao; Roy A Pleasants
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-04-15

4.  Costs of chronic obstructive pulmonary disease in urban areas of China: a cross-sectional study in four cities.

Authors:  Xiaoying Chen; Na Wang; Yue Chen; Tian Xiao; Chaowei Fu; Biao Xu
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-10-19

Review 5.  Disease burden of COPD in China: a systematic review.

Authors:  Bifan Zhu; Yanfang Wang; Jian Ming; Wen Chen; Luying Zhang
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-04-27

6.  Distributional benefits of tobacco tax and smoke-free workplaces in China: A modeling study.

Authors:  Stéphane Verguet; Gillian Tarr; Cindy L Gauvreau; Sujata Mishra; Prabhat Jha; Lingrui Liu; Yue Xiao; Yingpeng Qiu; Kun Zhao
Journal:  J Glob Health       Date:  2017-12       Impact factor: 4.413

7.  Economic Burden of Major Diseases in China in 2013.

Authors:  Xianyan Song; Lan Lan; Ting Zhou; Jin Yin; Qiong Meng
Journal:  Front Public Health       Date:  2021-05-19

Review 8.  Current status and preventive strategies of chronic obstructive pulmonary disease in China: a literature review.

Authors:  Zhenyu Quan; Guanghai Yan; Zhiguang Wang; Yan Li; Jie Zhang; Ting Yang; Hongmei Piao
Journal:  J Thorac Dis       Date:  2021-06       Impact factor: 2.895

9.  Validity of COPD diagnoses reported through nationwide health insurance systems in the People's Republic of China.

Authors:  Om P Kurmi; Julien Vaucher; Dan Xiao; Michael V Holmes; Yu Guo; Kourtney J Davis; Chen Wang; Haiyan Qin; Iain Turnbull; Peng Peng; Zheng Bian; Robert Clarke; Liming Li; Yiping Chen; Zhengming Chen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-03-01

10.  Hospitalization Trends in Adult Patients with COPD and Other Respiratory Diseases in Northeast China from 2005 to 2015.

Authors:  Honglei Liu; Ni Wang; Wei Chen; Wenyan Liu; Shiping Wang; Jianbo Lei; Hui Chen
Journal:  Biomed Res Int       Date:  2018-02-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.